Still, TROP2 remains attractive: the TROPHIT-1 phase II/III trial is comparing SG vs SOC in refractory mCRC, and datopotamab deruxtecan (Dato-DXd)-a TROP2-DXd ADC with strong bystander effect-is being tested in CRC in TROPION-PanTumor03. Here, TACSTD2 is linked to colorectal carcinoma.